Thiopeptides are posttranslationally-processed macrocyclic peptide metabolites, characterized by extensive backbone and side chain modifications that include a six-membered nitrogenous ring, thioazol(in)e/oxazol(in)e rings, and dehydrated amino acid residues. Thiostrepton A, produced by Streptomyces laurentii ATCC 31255, is one of the more structurally complex thiopeptides, containing a second macrocycle bearing a quinaldic acid. Thiostrepton A and other thiopeptides are of great interest due to their potent activities against emerging antibiotic-resistant Gram-positive pathogens, in addition to their antimalarial and anticancer properties. The ribosomal origins for thiopeptides have been established, however, few details are known concerning the posttranslational modification steps. Alteration to the primary amino acid sequence of the precursor peptide provides an avenue to probe the substrate specificity of the thiostrepton A posttranslational machinery. The information gathered from current studies can also be used to refine thiostrepton’s structure-activity relationship, providing insight into the key features of its scaffold that impart specificity toward each biological target. A fosmid-dependent biosynthetic engineering platform for thiostrepton A was developed and a series of thiostrepton analogs were successfully produced adapting this method. The seventh residue of thiostrepton A is predicted to be critical for the metabolite’s antibacterial activity. Our results were consistent this hypothesis and demonstrated that substitution of Thr7 in the thiostrepton A precursor peptide disrupts both biological activity and successful biosynthesis of the analogs. The thiostrepton biosynthetic machinery’s tolerances toward structural variation at the second and fourth positions of the TsrA core peptide were probed by the saturation mutagenesis of Ala2 and Ala4, respectively. Eight thiostrepton Ala2 variants were isolated with two analogs truncated at the N-terminus by one amino acid, bearing a shortened quinaldic acid-containing macrocycle. Our results suggested that the identity of the core peptide second residue influences the biosynthesis of a thiostrepton analog, however, not essential for the antibacterial and proteasome inhibitory activities of the full-length variants. Additionally, the quinaldic acid loop size affects thiostrepton’s antibacterial potency, but is not critical for the proteasome inhibitory activity. Sixteen thiostrepton analogs were isolated from Ala4 mutagenesis studies. We demonstrated that the identity of the amino acid residue at the fourth position in the thiostrepton scaffold is not critical to inhibit either the ribosome or the proteasome in vitro.

Among the myriad of naturally occurring bioactive compounds are the aminocyclopentitol-containing natural products that represent a family of sugar-derived microbial secondary metabolites, such as the antibiotics pactamycin, allosamidin, and trehazolin. Pactamycin, a structurally unique aminocyclitol antibiotic isolated from Streptomyces pactum, consists of a 5-membered ring aminocyclitol (cyclopentitol) unit, two aromatic rings (6-methylsalicylic acid (6-MSA) and 1-(3-Amino-phenyl)-ethanone or 3-aminoacetophenone) and a 1,1-dimethylurea. It has pronounced antibacterial, antitumor, antiviral, and antiplasmodial activities, but its development as a clinical drug was hampered by its broad cytotoxicity. Efforts to modulate its pharmacological and toxicity properties by structural modifications using synthetic organic chemistry have been difficult due to the complexity of its chemical structure. As part of our ongoing studies on the biosynthesis of aminocyclitol-derived bioactive natural products, we have identified the biosynthetic gene cluster of pactamycin in S. pactum ATCC 27456, which paves the way for a better understanding of pactamycin biosynthesis and generating novel pactamycin analogs through biosynthetic engineering. Through gene inactivations, feeding experiments, and in vitro enzymatic assay, we studied the biosynthesis of pactamycin, which include the modes of formation of the unique cyclopentitol unit, the 3-aminoacetophenone and the 6-methyl salicylic acid moieties. Armed with the tools needed to genetically engineer target strains of S. pactum, we were able to produce novel analogs of this untapped-class of natural products. TM-026 was generated from a ΔptmH (a radical SAM C-methyltransferase gene) mutant, whereas TM-025 was generated from a ΔptmH/ΔptmQ (a polyketide synthase gene) double knockout mutant. Both compounds show potent antimalarial activity, but lack significant antibacterial activity, and are about 10-30 times less toxic than pactamycin toward mammalian cells. The results suggest that distinct ribosomal binding selectivity or new mechanism(s) of action may be involved in their plasmodial growth inhibition, which may lead to the discovery of new antimalarial drugs and identification of new molecular targets within malarial parasites. TM-035 was also isolated from a ΔptmH mutant. However, we found that TM-035 showed no activity against bacteria, malarial parasites, and most tested mammalian cells, but it has potent growth inhibitory activity against two well-established human head and neck squamous cell carcinomas (SCC025 and SCC104) (IC₅₀ 725 nM) in an in vitro assay. More intriguingly, the compound is significantly less active against human primary epidermal keratinocytes (HPEK), demonstrating an interesting biological phenomenon and outstanding cell type selectivity, which may lead to the development of new anticancer chemotherapy. The production yield of pactamycin and its congeners under laboratory conditions is relatively low. This has hampered both mechanistic and preclinical studies of these promising compounds. To deepen our understanding of pactamycin biosynthesis and engineer mutant strains with improved production yields, we investigated pathway specific regulatory genes, ptmF and ptmE. Based on gene inactivation and RT-PCR studies, we found that the PtmF-PtmE system controls the transcription of the whole biosynthetic gene cluster. The results provide important insight into regulation of pactamycin biosynthesis and will contribute to future studies that aim at engineering high producing strains of S. pactum. / Graduation date: 2012 / Access restricted to the OSU Community at author's request from Feb. 28, 2012 - Feb. 28, 2013